drugset / Trial / NCT03566576
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Pemetrexed/Docetaxel in Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer , to provide a reference of dosage for Phase II clinical trials
Timeline
- Start
- 2018-07-01
- Primary completion
- 2018-09-01
- Completion
- 2018-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |